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HRV has been widely used to evaluate the control exerted by the autonomic
nervous system on cardiovascular activities, including vagal and sympathetic
components.
The aim of this study was to evaluate changes in HRV induced by BoNT-A
(NT-201) injection in spastic stroke patients.
Methods.– Eleven stroke survivors with spastic hemiplegia were injected with
IncobotulinumtoxinA (100 units:2 mL of 0.9% NaCl), with doses ≥ 600 UI
(maximal dose < 12 UI/Kg). They received two ECG registrations of 30 min
each, the first 24 h before injection and the second 10 days after.
Linear and non-linear HRV variables were obtained with HRV analysis
software.
Results.– None of the variable considered for time, frequency domain and non-
linear domain suffer significant changes after BoNT-A injection.
Conclusions.– High doses of BoNT-A do not influence cardiac autonomic drive.
Moreover, no clinical adverse events of any kind occurred in anyone of our
patients after NT-201 injection.
http://dx.doi.org/10.1016/j.rehab.2014.03.170
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Background.– Previous results in patients injected with abobotulinum toxin
A and onabotulinum toxin A have shown that injection intervals shorter than
2 months may increase the risk for neutralising antibody formation and treat-
ment non-response. As a result, for the last 10 years, we have adopted longer
intervals to treat patients with spasticity and/or dystonia secondary to stroke.
It has been showed that incobotulinum toxin A does not induce neutralising
antibodies.
Observations.–
Methods.– Ten patients with spasticity and/or dystonia due to stroke underwent
a booster injection one month after the first injection. The clinical results were
compared to those previously obtained in the same 10 patients using a single
injection. Secondary dystonia was evaluated using the Unified Dystonia Rating
Scale (UDRS), while spasticity was evaluated according to the Modified Ash-
worth Scale (MAS).
Results.– They showed that the booster injection protocol induced an improve-
ment in 8 subjects. In the remaining 2 subjects, we did not find any difference
between the results obtained using the single and the booster injection protocols.
Conclusions.– The use of a booster injection improve the clinical out-
come in patients with spasticity and/or dystonia after stroke, allowing
an optimal treatment of those muscles that poorly responded to the first
injection.
http://dx.doi.org/10.1016/j.rehab.2014.03.171
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Background.– SPACE, an international, non-interventional study, is collecting
effectiveness, safety and quality of life (QoL) data on botulinum toxin type A
(BoNT-A) treatment for spasticity in a routine practice setting. Here, we present
interim analyses of the first treatment cycle.
Methods.– BoNT treatment-naïve adults with spasticity of any aetiology were
followed for up to 2 years. Data collected include global assessments of efficacy
(patient-rated [PGAE] and investigator-rated [IGAE]) and investigator global
assessment of tolerability (IGAT). Global assessments were made at the end of
the first treatment cycle and scored from 1 = very good to 4 = poor. PGAE/IGAE
responders were defined as patients with scores ≤ 3 = moderate.
Results.– The interim analyses include 648 patients* (61.9% male, mean [stan-
dard deviation] age 54.8 [15.6] years) who received 1 treatment cycle with
incobotulinumtoxinA (n = 435), onabotulinumtoxinA (n = 138) or abobotuli-
numtoxinA (n = 75). Overall, 468/510 (91.8%) patients were PGAE responders
and 476/500 (95.2%) patients were IGAE responders. IGAT was very good or
good for 467/500 (93.4%) patients.
*Interim analyses – data were not yet available for all patients
Conclusions.– For patients with focal spasticity, their first-ever BoNT-A treat-
ment cycle was efficacious and well tolerated. Longer-term data will assess the
benefits of BoNT-A injections over multiple treatment cycles.
http://dx.doi.org/10.1016/j.rehab.2014.03.172
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Background.– Previous studies have shown the efficacy of botulinum toxin type
A (BoNT-A) in the management of ambulant individuals with cerebral palsy
(CP). We evaluated the efficacy of incobotulinum toxin A (Xeomin®) injections
in children with dynamic equinus affected by hemiplegic CP in polycentric study.
Methods.– The efficacy of treatment was tested in 30 children aged from 2 to
18 years with spasticity more than 2 at Modified Ashworth Scale, injections were
performed in calf muscles up to 200 U, with electromyographic guidance. The
treatment efficacy was evaluated with the Modified Ashworth Scale, Tardieu
Scale, Active and Passive Range of motion and Walking test on 10 m. Clinical
data were collected at time 0 and at 1, 3 and 6 months after the injections.
Results.– Preliminary data showed good efficacy and tolerability of treatment
spasticity with botulinum toxin A in children.
Conclusions.– Incobotulinum toxin A seems to be as effective as other type A
botulinum toxins. The absence of proteins could be an advantage in the paediatric
population requiring repeated treatments over time.
http://dx.doi.org/10.1016/j.rehab.2014.03.173
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Background.– TOWER is a prospective, Phase IV, dose titration clinical trial
(NCT01603459) investigating the safety and efficacy of incobotulinumtoxinA
(Xeomin®) in patients with spasticity, deemed to require doses higher than
currently approved.
Methods.– Patients (18–80 years) with upper- and lower-limb spasticity of
the same body side due to cerebral causes, deemed by the investigator to
require total body doses up to 800 U of incobotulinumtoxinA per injection
cycle, will undergo 3 injection cycles (400, 600, and 800 U incobotulinum-
toxinA, respectively), each followed by 12- to 16-week observation periods
with telephone contacts at 1 and 2 weeks and follow-up visits at 4, 8, and
12-16 weeks post-treatment. Co-primary outcome measures are adverse events
and investigator’s global assessment of tolerability. Muscle tone (Ashworth
Scale), Resistance to Passive Movement Scale, Functional Ambulation Clas-
sification scale, Goal Attainment Scale, Disability Assessment Scale, quality
of life, antibody formation, and pulmonary function will also be asses-
sed.
Results.– As of October 2013, patients (enrolment target 150) are being recruited
at 33 sites throughout Europe, Canada and the USA.
Conclusions.– TOWER will provide important insights into the safety and
efficacy of higher than currently recommended incobotulinumtoxinA doses in
patients with multifocal upper- and lower-limb spasticity.
http://dx.doi.org/10.1016/j.rehab.2014.03.174
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Background.– Studies have demonstrated reduction of spastic dystonia with
sustained stretch. The aim of the present work was to evaluate the effects
of upper limb wrist-worn loading in a patient with elbow flexor spastic
dystonia.
Methods.– A 53-year old male with left spastic hemiparesis secondary to a
cerebral infarct 2 years prior has benefited from a 3-month rehabilitation pro-
gram, including botulinum toxin injections at the Neurorehabilitation Day
Hospital in Albert-Chenevier hospital, Créteil, France. Within this program
the patient has worn a loaded wrist splint (1.5 kg) daily. Every day, he repor-
ted the total loading time together with any untoward effects in a diary.
Once monthly we monitored spasticity with the Tardieu Scale and active
arm function with the Modified Frenchay Scale using blinded review by two
examiners.
Results.– Maximal range of passive motion against the elbow flexors (XV1)
increased from 144◦ to 164◦ (+20◦), angle of catch (XV3) from 92◦ to 116◦
(+24◦) and active motion range (A) from 78◦ to 92◦ (+14◦). Regarding active
limb function, score improved by 1/10 point for three tasks involving active
elbow extension.
Conclusion.– Upper limb loading may be of benefit in hemiparesis to reduce
elbow flexor spastic dystonia and improve functionality.
http://dx.doi.org/10.1016/j.rehab.2014.03.175
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Background.– Type A botulinum toxin has been used in paraspinal muscles
for several conditions like stiff-person syndrome, back pain in cerebral palsy,
chronic low back pain, X-linked dystonia-parkinsonism.
Methods.– A 30-years old woman developed a spastic quadriplegia with right
side more involved, after a severe stroke at the age of 19. Although she was
following a rehabilitation programme for several years, she only improved her
ability to walk slowly for up to 30 steps unaided.
Results.– After treatment with type A botulinum toxin (Botox) for 6 years in limb
muscles, during the last 2 years, she developed a scoliosis which interfered with
her gait pattern. Right paraspinal thoracic muscles were injected, with botulinum
toxin in 6 segments, using 20 U in each site. This treatment was repeated 4 times
each year. Patient improved posture in standing position and facilitated the gait
pattern and velocity. She could walk more than 50 steps without assistance,
without body shifting and with a faster gait speed.
Conclusions.– Administration of botulinum toxin A reduced the tone of para-
spinal and improves significantly improvement of gait pattern in quadriplegic
woman.
http://dx.doi.org/10.1016/j.rehab.2014.03.176
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Background.– Intrathecal baclofen has been used to treat lower limb spasticity
in hereditary spastic paraparesis. Botulinum toxin type A has also been used for
the same reason.
Methods.– We present three cases of women (aged 47, 58, and 59) with hereditary
spastic paraparesis treated in our PRM department.
Results.– Patients were under intramuscular antispastic treatment with 400 U of
type A botulinum toxin for two years period, in hip adductors, hamstrings and
triceps surae. After 4, 8, 12, 16, 20 and 24 months of botulinum toxin, Modi-
fied Ashworth Scale showed improvement of spasticity not enough to improve
the gait velocity, measured with 10 m walking test. Patients were referred to
Neurosurgical department where they were treated with permanent intrathecal
baclofen pump, after positive test of 50g baclofen intrathecally. MAS score
was also improved but with not significant improvement in gait pattern. Daily
living activities were improved.
Conclusions.– Both botulinum toxin and intrathecal baclofen can reduce spas-
ticity in hereditary spastic paraparesis. Walking ability of these persons is still a
big question depending on the degree of paralysis and the severity of the disease.
http://dx.doi.org/10.1016/j.rehab.2014.03.177
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